(418f) Plasmonic Metal Nanocatalysts As Platform for Continuous Synthesis of Drug Substances
AIChE Annual Meeting
2017
2017 Annual Meeting
Pharmaceutical Discovery, Development and Manufacturing Forum
Continuous Processing Technologies Applied in Drug Substance Development Chemistry
Tuesday, October 31, 2017 - 5:05pm to 5:27pm
Farshid Mohammadparast, Andishaeh Dadgar, Marimuthu Andiappan, School of Chemical Engineering, Oklahoma State University, Stillwater, OK, USA
Approximately 25% of all the reactions performed in the pharmaceutical industry consist of cross-coupling reactions. The cross-couplings have been traditionally carried out by homogeneous palladium (Pd) catalyzed batch processes. The National Science and Technology Council (NSTC) has recently identified the continuous manufacturing of pharmaceuticals as one of five manufacturing areas of emerging priority in the USA, revealing that continuous manufacturing of pharmaceuticals has the potential to reduce manufacturing cost by up to 40-50%. Given these advantages, in recent years, metal nanoparticle catalyzed cross-couplings have been of great interest since they can be used as a platform to switch cross-couplings from traditionally used batch mode to continuous flow mode. Additionally, heterogeneous metal nanocatalysts can be immobilized on a rigid support in the form of a packed-bed reactor, and therefore, can avoid the need for subsequent difficult steps to separate the catalyst and product.
In this contribution, we show that heterogeneous plasmonic metal nanocatalysts can be used as efficient catalysts to drive cross couplings. Specifically, we demonstrate that visible light can be used as a powerful tool to make plasmonic metal nanocatalysts as efficient photo-catalysts with activity and stability superior to that of traditionally used homogeneous Pd based catalysts. These plasmonic metal nanocatalysts can be used to design efficient cross-coupling flow processes to produce drug substances.